{
    "root": "d1618962-0dd9-4186-a383-74e823f5f7a2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ZEPZELCA",
    "value": "20250430",
    "ingredients": [
        {
            "name": "LURBINECTEDIN",
            "code": "2CN60TN6ZS",
            "drugbank_id": "https://go.drugbank.com/drugs/DB12674"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "LACTIC ACID, UNSPECIFIED FORM",
            "code": "33X04XA5AT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "zepzelca indicated treatment adult patients metastatic small cell lung cancer ( sclc ) disease progression platinum-based chemotherapy . indication approved accelerated approval based overall response rate duration response [ ( 14 ) ] . continued approval indication may contingent upon verification description benefit confirmatory trial ( ) .",
        "doid_entities": [
            {
                "text": "lung cancer (DOID:1324)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1324"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 recommended : 3.2 mg/m 2 every 21 days disease progression unacceptable toxicity . ( 2.1 ) \u2022 administer zepzelca intravenous infusion 60 minutes . ( 2.1 ) \u2022 consider premedication corticosteroids serotonin antagonists antiemetic prophylaxis . ( 2.5 ) \u2022 moderate hepatic impairment : recommended 1.6 mg/m 2 every 21 days disease progression unacceptable toxicity . ( 2.4 , 8.6 ) \u2022 severe hepatic impairment : avoid zepzelca . avoided , recommended 1.6 mg/m 2 intravenous infusion every 21 days disease progression unacceptable toxicity . ( 2.4 , 8.6 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "supplied zepzelca ( lurbinectedin ) injection supplied sterile , preservative-free , white off-white lyophilized powder single-dose clear glass vial . carton ( ndc 68727-712-01 ) contains 4 mg one single-dose vial . storage handling store refrigerated 2\u00b0c 8\u00b0c ( 36\u00b0f 46\u00b0f ) . zepzelca hazardous . follow applicable special handling disposal procedures1 .",
    "adverseReactions": "none .",
    "indications_original": "ZEPZELCA is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.\n                  This indication is approved under accelerated approval based on overall response rate and duration of response [see\n                     \n                         Clinical Studies (14)\n                     \n                     ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contraindications_original": "\u2022 Recommended Dosage : 3.2 mg/m 2 every 21 days until disease progression or unacceptable toxicity. ( 2.1 ) \u2022 Administer ZEPZELCA as an intravenous infusion over 60 minutes. ( 2.1 ) \u2022 Consider premedication with corticosteroids and serotonin antagonists for antiemetic prophylaxis. ( 2.5 ) \u2022 Moderate Hepatic Impairment : Recommended dosage is 1.6 mg/m 2 every 21\u00a0days until disease progression or unacceptable toxicity. ( 2.4 , 8.6 ) \u2022 Severe Hepatic Impairment : Avoid use of ZEPZELCA. If use cannot be avoided, the recommended dosage is 1.6 mg/m 2 by intravenous infusion every 21 days until disease progression or unacceptable toxicity. ( 2.4 , 8.6 )",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  ZEPZELCA (lurbinectedin) for injection is supplied as a sterile, preservative-free, white to off-white lyophilized powder in a single-dose clear glass vial. Each carton (NDC 68727-712-01) contains 4\u00a0mg in one single-dose vial.\n                  \n                     Storage and Handling\n                  \n                  Store refrigerated at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F).\n                  ZEPZELCA is a hazardous drug. Follow applicable special handling and disposal procedures1.",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "ZEPZELCA",
            "drugbank_id": "https://go.drugbank.com/drugs/DB12674"
        }
    ]
}